Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
